FGP declines, for the 11th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Certificates of analysis
Page 37 of 51 of this archive, newest first.
Sending the same vial twice, under two names
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
D-amino acids are invisible to mass spectrometry, and that is the whole problem
Stereochemical inversion changes the molecule, changes its biology, and changes its mass by exactly nothing.
CPC declines, for the 23rd time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at CPC in October, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Medutest result on a Xi'an semaglutide lot lands 3.3 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
SSA declines, for the 15th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What Sweden customs does to a parcel it has decided to examine
A gel pack has a finite thermal budget, and once it is spent the payload equilibrates with whatever is outside the box. The only question is how long that takes.
Independent analysis puts a WXT tirzepatide lot at 96.4%, against 93.6% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
VendorInvestigate result on a Wuxi semaglutide lot lands 2.1 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
Janoshik result on a Wuxi survodutide lot lands 2.9 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
Why a result on one vial says less than the trade needs it to
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
GGPeps declines, for the 15th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
VendorInvestigate result on a Guangzhou liraglutide lot lands 3.6 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
What “LC-MS: conforms” tells a reader, which is almost nothing
What the Journal asks for when it writes to a supplier about an identity claim, and how often it gets it.
Why a 0.036-dalton difference is the hardest number in peptide identity
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
Independent analysis puts a Homopeptide orforglipron lot at 99.1%, against 98.4% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Australia health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.